1. Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.

    Future Oncology 12(13):1565 (2016) PMID 27079926

    This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Patients with sAML (median ag...
  2. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.

    Clinical Lymphoma Myeloma and Leukemia 16(7):373 (2016) PMID 27349764

    Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare entity with no previous population-based study. We used the Surveillance, Epidemiology, and End Results 18 database to identify adult patients with SPTCL and peripheral T-cell lymphoma not otherwise specified (PTCL NOS) diagnosed b...
  3. Is watch and wait still acceptable for patients with low-grade follicular lymphoma?

    Blood 127(23):2804 (2016) PMID 26994147

    Follicular lymphoma (FL) represents more than 20% of all non-Hodgkin lymphomas worldwide and approximately 30% of the non-Hodgkin lymphomas diagnosed in the United States. Although occasionally localized at the time of diagnosis, most patients have disseminated disease. However, patients are fre...
  4. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience.

    Leukemia & Lymphoma 57(6):1327 (2016) PMID 26377137

    The objective of this retrospective study (N = 169) was to compare the overall survival (OS) of different subtypes of mantle cell lymphoma (MCL) treated by the Nebraska Lymphoma Study Group between 1984 and 2012. The overall response rate to various therapies including stem cell transplant (SCT)...
  5. Relative frequency of non-Hodgkin lymphoma subtypes in selected centres in North Africa, the middle east and India: a review of 971 cases.

    British Journal of Haematology 172(5):699 (2016) PMID 26684877

    Comparative data regarding the distribution of non-Hodgkin lymphoma (NHL) subtypes in North Africa, the Middle East and India (NAF/ME/IN) is scarce in the literature. In this study, we evaluated the relative frequencies of NHL subtypes in this region. Five expert haematopathologists classified 9...
  6. Non-Hodgkin lymphoma in Southern Africa: review of 487 cases from The International Non-Hodgkin Lymphoma Classification Project.

    British Journal of Haematology 172(5):716 (2016) PMID 26898194

    Comparative data on the distribution of non-Hodgkin lymphoma (NHL) subtypes in Southern Africa (SAF) is scarce. In this study, five expert haematopathologists classified 487 consecutive cases of NHL from SAF using the World Health Organization classification, and compared the results to North Am...
  7. Real Personalized Medicine.

    Journal of the National Comprehensive Cancer Ne... 14(2):233 (2016) PMID 26850491

  8. Evolution.

    Journal of Oncology Practice 12(1):1 (2016) PMID 26733618

  9. Trends in Use of Radiation Therapy for Hodgkin Lymphoma From 2000 to 2012 on the Basis of the National Cancer Data Base.

    Clinical Lymphoma Myeloma and Leukemia 16(1):12 (2016) PMID 26702473

    Hodgkin lymphoma (HL) has come a long way from being a disease with high mortality to being highly curable, which thereby exposes survivors to the potential for long-term toxicities. Our aim was to analyze the National Cancer Data Base for trends in radiation therapy use among all stages of HL f...
  10. Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project.

    Annals of Hematology 95(2):245 (2016) PMID 26537613

    Large and systematic studies of non-Hodgkin lymphoma (NHL) in the Far East (FE) with good comparative data are scarce in the literature. In this study, five expert hematopathologists classified 730 consecutive cases of newly-diagnosed NHL from four sites in the FE (excluding Japan) using the Wor...
  11. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.

    JAMA Oncology 2(1):134 (2016) PMID 26606114

  12. To Surveil or Not to Surveil.

    Journal of Clinical Oncology 33(34):3983 (2015) PMID 26438116

  13. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis.

    American Journal of Hematology 90(11):1052 (2015) PMID 26270899

    The use of radiation (RT) in primary mediastinal large B-cell lymphoma (PMBCL) may predispose young patients to the risk of cardiopulmonary toxicities and secondary malignancies. We used Surveillance, Epidemiology and End Results (SEER) 18 database to compare the overall survival (OS) difference...
  14. Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

    Journal of Oncology Practice 11(6):511 (2015) PMID 26199293

  15. Classification of non-Hodgkin lymphoma in South-eastern Europe: review of 632 cases from the international non-Hodgkin lymphoma classification project.

    British Journal of Haematology 171(3):366 (2015) PMID 26213902

    The distribution of non-Hodgkin lymphoma (NHL) subtypes varies around the world, but a systematic study of South-eastern Europe (SEEU) has never been done. Therefore, we evaluated the relative frequencies of NHL subtypes in three SEEU countries--Croatia, Romania and Macedonia. Five expert haemat...
  16. Demographic and other characteristics of nodal non-Hodgkin's lymphoma managed in academic versus non-academic centers.

    Therapeutic Advances in Hematology 6(5):223 (2015) PMID 26425335 PMCID PMC4556968

    Cancer therapy and outcomes are known to be affected by various demographic features and hospital types. We aimed to identify the characteristics of non-Hodgkin's lymphoma (NHL) patients associated with receipt of care at academic centers. This is a retrospective study of all patients diagnosed ...
  17. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.

    Scandinavian Journal of Haematology 95(4):361 (2015) PMID 25892213

    Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29-yr-old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic r...
  18. Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.

    Clinical Lymphoma Myeloma and Leukemia 15(10):606 (2015) PMID 26184063

    Central nervous system complications (CNSC) can be the cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to determine the incidence of CNSC and its impact on survival. This retrospective cohort study included patients...
  19. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

    Journal of Clinical Oncology 33(28):3199 (2015) PMID 26169616

    To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). The American Society of Clinical Oncology convened an Update Committee and conducted a systematic review of randomized clinical trials, meta-analyses, and systematic ...
  20. Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy.

    American Journal of Clinical Oncology 38(4):377 (2015) PMID 24192805

    Doxorubicin is associated with a cumulative dose-dependent nonischemic cardiomyopathy. Cardiac magnetic resonance imaging (cMRI) is able to examine both structural and functional components of the myocardium. Our aim was to assess the myocardial changes in non-Hodgkin lymphoma patients undergoin...